Stocks making the biggest moves premarket: Netflix, United Airlines, Procter & Gamble, Oracle and more
January 22, 2025 - by Editor Prism MarketView
Here are the companies that were making big waves before the opening bell.
- The stock of this streaming giant surged over 15% following a robust top- and bottom-line beat announced on Tuesday night. Earnings per share ($4.27) exceeded analyst predictions as did the $10.25 billion revenue for the final quarter. Netflix has also crossed the 300 million paid subscribers milestone this quarter.
- Stock for this airline soared 5% after projecting a more optimistic outlook than anticipated. United’s forecast of earnings between 75 cents and $1.25 per share for the first quarter of 2025 surpasses the 54 cents per share predicted by analysts.
- Continuing its downward trend post-inauguration, the parent company of Truth Social stumbled 2%, following an 11% fall in shares on Tuesday.
- Meeting analysts’ expectations, P&G’s shares rose 3% as the company’s second-quarter earnings and revenue topped forecasts. Rising demand for household staples played a role in this growth.
- The software corporation’s shares spiked over 10% in response to President Donald Trump’s announcement of project “Stargate”, a project in partnership with OpenAI and Softbank to invest up to $500 billion in U.S. AI infrastructure.
- Despite a downgrade in shares from Barclays, the automaker’s shares dipped nearly 2% anticipating volume headwinds and cost improvement uncertainties.
- Fourth-quarter sales seemed to have disappointed investors, as shares of this healthcare firm dropped nearly 2%.
- The data storage company’s shares vaulted more than 6% after the release of healthy fiscal second-quarter results.
- The energy firm saw a modest increase of about 1% in shares, despite falling short of revenue expectations.
- Stock of this insurer rocketed more than 5% after the corporation’s fourth-quarter results well exceeded estimates.
- The company’s shares fell close to 4% after the aviation and defense company fell short of expected top-line estimates.
- The pharmaceutical giant’s shares dropped 1.5% despite narrowly exceeding fourth-quarter expectations, as the company’s sales forecast for 2025 was slightly below analyst predictions.
